CN113105569B - 柚皮苷-壳寡糖偶联物及其制备方法和应用 - Google Patents
柚皮苷-壳寡糖偶联物及其制备方法和应用 Download PDFInfo
- Publication number
- CN113105569B CN113105569B CN202110352150.9A CN202110352150A CN113105569B CN 113105569 B CN113105569 B CN 113105569B CN 202110352150 A CN202110352150 A CN 202110352150A CN 113105569 B CN113105569 B CN 113105569B
- Authority
- CN
- China
- Prior art keywords
- naringin
- conjugate
- chitosan oligosaccharide
- chitooligosaccharide
- chitosan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 claims abstract description 53
- 229930019673 naringin Natural products 0.000 claims abstract description 53
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 claims abstract description 53
- 229940052490 naringin Drugs 0.000 claims abstract description 53
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 21
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 241000607142 Salmonella Species 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims 3
- 238000010168 coupling process Methods 0.000 claims 3
- 238000005859 coupling reaction Methods 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 238000001704 evaporation Methods 0.000 abstract description 3
- 244000144972 livestock Species 0.000 abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 3
- 230000003647 oxidation Effects 0.000 abstract description 3
- 238000007254 oxidation reaction Methods 0.000 abstract description 3
- 244000144977 poultry Species 0.000 abstract description 3
- 239000002904 solvent Substances 0.000 abstract description 3
- 238000003756 stirring Methods 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract description 2
- 238000001291 vacuum drying Methods 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 abstract 2
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 229920001542 oligosaccharide Polymers 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 5
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 5
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 150000002482 oligosaccharides Chemical class 0.000 description 5
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 238000005411 Van der Waals force Methods 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000006069 physical mixture Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FTVWIRXFELQLPI-CYBMUJFWSA-N (+)-Naringenin Natural products C1=CC(O)=CC=C1[C@@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-CYBMUJFWSA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000008265 rhamnosides Chemical class 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/06—Benzopyran radicals
- C07H17/065—Benzo[b]pyrans
- C07H17/07—Benzo[b]pyran-4-ones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
- C07H5/06—Aminosugars
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Animal Husbandry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Materials Engineering (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种柚皮苷‑壳寡糖偶联物及其制备方法和应用，按照如下步骤制备：将柚皮苷和壳寡糖分别配制成乙醇溶液，然后混合，搅拌反应完后，蒸去溶剂，真空干燥得到产品。柚皮苷溶解性提高，可应用于抗氧化、抑菌、杀菌方面。为柚皮苷在畜禽饲料领域、生物医疗领域和功能保健食品等领域的开发应用提供新思路。
Description
技术领域
本发明涉及一种柚皮苷-壳寡糖偶联物及其制备方法和应用，属于化合物领域。
背景技术
柚皮苷是由4’,5,7-三羟基二氢黄酮苷元与鼠李糖苷[2-O-(6-脱氧-α-L-甘露聚糖)-β-D-葡萄糖]所构成的化合物，是一种双氢黄酮类化合物。由于A环和B环之间完全没有共轭，所以在282nm有强烈的紫外吸收峰，使柚皮苷显示多种生物学活性和药理作用。其具有抗炎、抗病毒、抗癌、抗突变、抗过敏、抗溃疡、镇痛、降血压活性，能降血胆固醇、减少血栓的形成，改善局部微循环和营养供给，可用于生产防治心脑血管疾病。
柚皮苷广泛存在于柑桔皮渣中，具有作为人类膳食补充剂和畜禽天然抗生素的潜力。但由于其溶解度较低，味道偏苦，很少被直接使用，因此提高柚皮苷的生物利用度显得尤为重要。
发明内容
本为了解决上述技术问题，本发明提供了一种柚皮苷-壳寡糖偶联物，以提高其溶解性、生物活性和生物利用度，本发明第二目的在于提供该种柚皮苷-壳寡糖偶联物的制备方法，第三目的在于提供其应用。
为了实现本发明的上述第一目的，本发明提供了一种柚皮苷-壳寡糖偶联物，其结构式为：
n＝2-20。
上述方案中：所述壳寡糖的分子量≤3000。
上述方案中：所述壳寡糖的分子量为800-1000。
本发明的第二目的是这样实现的：一种柚皮苷-壳寡糖偶联物的制备方法，其特征在于，按照如下步骤制备：将柚皮苷和壳寡糖分别配制成乙醇溶液，然后混合，搅拌反应完后，蒸去溶剂，真空干燥得到产品。
上述方案中：搅拌采用涡旋振荡。
所述的柚皮苷-壳寡糖偶联物在清除自由基、抗氧化上的应用。
所述自由基为ABTS+、DPPH、-OH。
所述柚皮苷-壳寡糖偶联物作为抑菌、杀菌药物的应用。
柚皮苷与壳寡糖、低聚壳寡糖通过氢键或范德华力等非共价键形成稳定偶联物可改善柚皮苷的溶解性，经过高效液相色谱分析偶联物的水溶性，柚皮苷-壳寡糖偶联物在原有柚皮苷的溶解度上提高约54.8倍。
通过ABTS+、DPPH、-OH三种方法测定柚皮苷及偶联物的体外抗氧化活性，偶联物对DPPH自由基清除效果尤为明显，对ABTS+自由基和-OH自由基的清除效果相比柚皮苷而言也有所提升。偶联物对大肠杆菌、金黄色葡萄球菌和鼠伤寒沙门氏菌的抑制效果也大大增强，且偶联物D、偶联物E、偶联物d和偶联物e对致病菌有一定的杀菌效果。这为柚皮苷在畜禽饲料领域、生物医疗领域和功能保健食品等领域的开发应用提供新思路。
附图说明：
图1为柚皮苷、柚皮苷与壳寡糖(分子量3000左右)物质的量比2：1，1：1，1：2，1：3，1：5形成的柚皮苷-壳寡糖偶联物扫描电镜图。
图2为柚皮苷、柚皮苷与低聚寡聚糖(分子量800-1000)物质的量比2：1，1：1，1：2，1：3，1：5柚皮苷-低聚壳寡糖偶联物扫描电镜图。
图3为柚皮苷、壳寡糖、柚皮苷与寡聚糖(分子量3000左右)按照物质的量比2：1，1：1，1：2，1：3，1：5制成的柚皮苷-壳寡糖偶联物傅里叶红外光谱图。
图4为柚皮苷、低聚壳寡糖、柚皮苷与低聚寡聚糖(分子量800-1000)按照物质的量比2：1，1：1，1：2，1：3，1：5制成的柚皮苷-低聚壳寡糖偶联物傅里叶红外光谱图。
图5为柚皮苷、壳寡糖、柚皮苷与寡聚糖(分子量3000左右)按照物质的量比2：1，1：1，1：2，1：3，1：5柚皮苷-壳寡糖偶联物X射线衍射图。
图6为柚皮苷、低聚壳寡糖、柚皮苷与低聚寡聚糖(分子量800-1000)物质的量比2：1，1：1，1：2，1：3，1：5制成的柚皮苷-低聚壳寡糖偶联物X射线衍射图。
图7为柚皮苷、物理混合物、柚皮苷与寡聚糖(分子量3000左右)按照物质的量比2：1，1：1，1：2，1：3，1：5制成的柚皮苷-壳寡糖偶联物溶解度图。
图8为柚皮苷、物理混合物、柚皮苷与低聚寡聚糖(分子量800-1000)物质的量比2：1，1：1，1：2，1：3，1：5柚皮苷-低聚壳寡糖偶联物溶解度图。
图9为柚皮苷、壳寡糖、低聚壳寡糖、偶联物的抗氧化活性。
具体实施方式：
下面结合实施例对本发明作进一步详细说明。
实施例1
以柚皮苷和壳寡糖(分子量3000左右)为原料，分别按摩尔比为2：1、1：1、1：2、1：3、1：5的比例，用95％乙醇分别配制柚皮苷溶液和壳寡糖溶液，将两者混合，涡旋振荡5min。然后在45℃下旋转蒸发挥去大部分溶剂，于60℃真空干燥12h，粉碎过筛即得柚皮苷-壳寡糖偶联物。得到的偶联物同时分别用偶联物A、偶联物B、偶联物C、偶联物D、偶联物E表示。
以柚皮苷和低聚壳寡糖(分子量800-1000)为原料，按照上述方法，可制得柚皮苷-低聚壳寡糖偶联物。得到的偶联物同时分别用偶联物a、偶联物b、偶联物c、偶联物d、偶联物e表示。
制备后通过场发射扫描电镜、傅里叶红外光谱、X射线衍射仪测定偶联物结构。结果见图，图中Naringin表示柚皮苷。
柚皮苷和偶联物对大肠杆菌、金黄色葡萄球菌、沙门氏菌的最低抑菌浓度和最低杀菌浓度见表1。
表1柚皮苷和偶联物对大肠杆菌、金黄色葡萄球菌、沙门氏菌的最低抑菌浓度和最低杀菌浓度。表中MIC表示最低抑菌浓度，MBC表示最低杀菌浓度。
本发明选用分子量近1000和3000的壳寡糖，制备不同比例的柚皮苷-壳寡糖偶联物，通过扫描电子显微镜SEM、傅里叶红外光谱FT-IR、X射线衍射仪XRD分析比较柚皮苷、柚皮苷-壳寡糖和柚皮苷-低聚壳寡糖偶联物的理化性质。结果表明柚皮苷与壳寡糖、低聚壳寡糖通过氢键或范德华力等非共价键形成稳定偶联物。经过高效液相色谱分析偶联物的水溶性，柚皮苷-壳寡糖偶联物在原有柚皮苷的溶解度上提高约54.8倍。通过ABTS+、DPPH、-OH三种方法测定柚皮苷及偶联物的体外抗氧化活性，偶联物对DPPH自由基清除效果尤为明显，对ABTS+自由基和-OH自由基的清除效果相比柚皮苷而言也有所提升，其中偶联物A和偶联物e的抗氧化活性最高。通过抑菌实验分析得偶联物对大肠杆菌、金黄色葡萄球菌和鼠伤寒沙门氏菌的抑制效果也大大增强，且偶联物D、偶联物E、偶联物d和偶联物e对致病菌有一定的杀菌效果，可以达到抗生素土霉素的杀菌效果，是潜在的抑菌剂。总体而言，柚皮苷与壳寡糖在比例为2：1时形成的偶联物，抗氧化活性较好。在比例1：3和1：5时形成的偶联物，柚皮苷溶出率和抑菌活性较好。柚皮苷与低聚壳寡糖在比例1：3和1：5时形成的偶联物，其柚皮苷溶出率、抗氧化和抑菌活性均较好。
以上内容是结合具体的优选实施方式对本发明所作的进一步详细说明，不能认定本发明的具体实施只局限于这些说明，对于本发明所属技术领域的普通技术人员来说，在不脱离本发明构思的前提下，还可以做出若干简单推演或替换，都应当视为属于本发明的保护范围。
Claims (3)
1.柚皮苷-壳寡糖偶联物在制备用于杀灭沙门氏菌或金黄色葡萄球菌的药物中的用途，其特征在于：由柚皮苷和壳寡糖按照摩尔比1:5偶联得到所述偶联物，所述壳寡糖的分子量为3000Da。
2.柚皮苷-壳寡糖偶联物在制备用于杀灭沙门氏菌的药物中的用途，其特征在于：由柚皮苷和壳寡糖按照摩尔比1:3偶联得到所述偶联物，所述壳寡糖的分子量为3000Da。
3.柚皮苷-壳寡糖偶联物在制备用于杀灭大肠杆菌的药物中的用途，其特征在于：由柚皮苷和壳寡糖按照摩尔比1:3偶联得到所述偶联物，所述壳寡糖的分子量为800-1000Da。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210692080.6A CN114917355B (zh) | 2021-03-31 | 2021-03-31 | 柚皮苷-壳寡糖偶联物及其制备方法和应用 |
| CN202110352150.9A CN113105569B (zh) | 2021-03-31 | 2021-03-31 | 柚皮苷-壳寡糖偶联物及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110352150.9A CN113105569B (zh) | 2021-03-31 | 2021-03-31 | 柚皮苷-壳寡糖偶联物及其制备方法和应用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210692080.6A Division CN114917355B (zh) | 2021-03-31 | 2021-03-31 | 柚皮苷-壳寡糖偶联物及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113105569A CN113105569A (zh) | 2021-07-13 |
| CN113105569B true CN113105569B (zh) | 2022-07-15 |
Family
ID=76713494
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210692080.6A Active CN114917355B (zh) | 2021-03-31 | 2021-03-31 | 柚皮苷-壳寡糖偶联物及其制备方法和应用 |
| CN202110352150.9A Active CN113105569B (zh) | 2021-03-31 | 2021-03-31 | 柚皮苷-壳寡糖偶联物及其制备方法和应用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210692080.6A Active CN114917355B (zh) | 2021-03-31 | 2021-03-31 | 柚皮苷-壳寡糖偶联物及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN114917355B (zh) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4202439B2 (ja) * | 1996-10-01 | 2008-12-24 | 江崎グリコ株式会社 | フラボノイド可溶化法、その糖転移法及び高濃度フラボノイド溶液 |
| CN105506029B (zh) * | 2016-01-06 | 2019-03-29 | 西南大学柑桔研究所 | 用柑橘皮制备抗真菌果胶低聚糖的方法及其应用和柑橘保鲜方法 |
| CN107568737A (zh) * | 2017-08-07 | 2018-01-12 | 天津科技大学 | 利用壳寡糖改善橙皮苷水溶性和抗氧化性的方法 |
| CN108484693B (zh) * | 2018-03-14 | 2020-08-11 | 中科荣信（苏州）生物科技有限公司 | 一种壳寡糖-抗生素偶联物及其制备方法和应用 |
| CN109430878B (zh) * | 2018-10-19 | 2022-04-05 | 天津科技大学 | 芦丁壳寡糖复合物及其制备方法和应用 |
-
2021
- 2021-03-31 CN CN202210692080.6A patent/CN114917355B/zh active Active
- 2021-03-31 CN CN202110352150.9A patent/CN113105569B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114917355B (zh) | 2023-07-18 |
| CN114917355A (zh) | 2022-08-19 |
| CN113105569A (zh) | 2021-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101344432B1 (ko) | 수용성 크실란에 의한 난용성 또는 불용성 물질의 용매에 대한 친화성 향상 | |
| Prashanth et al. | Antibacterial activity of Punica granatum | |
| Wu et al. | A deep insight into mechanism for inclusion of 2R, 3R-dihydromyricetin with cyclodextrins and the effect of complexation on antioxidant and lipid-lowering activities | |
| EP3120843A1 (en) | Composition for oral intake | |
| CN107922452A (zh) | 一种氧化型β‑1,4‑寡聚葡萄糖醛酸及其制备方法和用途 | |
| US9732079B2 (en) | Yellow reduced pyrroloquinoline quinone crystal and method of producing the same, and food, pharmaceutical, gel, composition and method of producing composition | |
| CN106074471B (zh) | 一种新型抑菌剂六氢β-酸环糊精包合物的制备方法 | |
| WO2013061455A1 (ja) | 新規なレスベラトロール重合化合物又はその薬学的に許容可能な塩 | |
| KR101738232B1 (ko) | 진세노사이드 화합물 k 및 글리콜 키토산의 결합체 및 이의 항암 용도 | |
| KR20150102539A (ko) | 수용성 은행잎 추출물 및 이의 제조방법 | |
| Mouriya et al. | Green synthesis of Cicer arietinum waste derived silver nanoparticle for antimicrobial and cytotoxicity properties | |
| CN113105569B (zh) | 柚皮苷-壳寡糖偶联物及其制备方法和应用 | |
| Chahardoli et al. | Galbanic acid, a sesquiterpene coumarin as a novel candidate for the biosynthesis of silver nanoparticles: In vitro hemocompatibility, antiproliferative, antibacterial, antioxidant, and anti-inflammatory properties | |
| WO2013015519A1 (ko) | 비타민나무 잎으로부터 분리한 이소람네틴-3-글루코시드-7-람노시드를 유효성분으로 함유하는 항산화용 조성물 | |
| CN112209988A (zh) | 一种茶皂苷元缩氨基硫脲锌配合物及其制备方法与应用 | |
| JP2017131215A (ja) | 経口液体組成物 | |
| JP2012246243A (ja) | 新規レスベラトロール誘導体 | |
| CN108794473A (zh) | 一种苝酰亚胺-野尻毒素衍生物及其制备方法与应用 | |
| CN108864236A (zh) | 一种1,2,3,4,6-o-五没食子酰葡萄糖锗络合物及其制备方法和应用 | |
| CN110403909B (zh) | 一种莱菔素粉剂及其制备方法 | |
| JP5891970B2 (ja) | 新規ケルセチン誘導体 | |
| CN110305165B (zh) | 一种胍基木犀草素-铬（iii）络合物及其制备方法 | |
| KR20200037976A (ko) | 녹차 사포닌을 유효성분으로 함유하는 가금류 항균용 조성물 | |
| CN110437284B (zh) | 一种5＇,8-二（二甲基双胍基）木犀草素-铬（iii）络合物 | |
| CN113069554B (zh) | 一种齐墩果酸季铵盐-肝素-壳聚糖纳米粒的制备方法及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |